The global Male Infertility Market is expected to reach USD
4.7 billion by 2025, according to a new report by Grand View Research, Inc.
Globally, increasing infertility in male and advancements in diagnostic tests
have been major factors driving the market growth. In addition, growing
consciousness regarding factors causing male infertility and Assisted
Reproductive Technology (ART) has led to increased adoption of treatment.
Furthermore, increasing aging
population, rising obesity, and other lifestyle-associated diseases causing
infertility are likely to boost the market during the forecast period. In the
U.S., one third of infertility cases are due to female factor, one third due to
male factors, and remaining one third are unexplained.
DNA fragmentation technique was
the largest segment in male infertility tests market in 2016 and is expected to
maintain its dominance during the forecast period due to rapid growth in next
few years. High cost and increasing adoption in developed countries due to
higher sensitivity and reliable analysis of sperm DNA integrity are the key
factors for its dominance.
In 2016, ART segment dominated
in the treatment market due to high success rate. In Vitro Fertilization and
Intracytoplasmic Sperm Injection (ICSI) are the major ARTs used. Medications
include corticosteroids and hormonal therapy; however, they are effective in
very few cases. Hence, low demand, less adherence, and lower cost as compared
to ART are likely to slow the growth of the medication market.
Further Key Findings From the Report Suggest:
- Rising demand of ARTs across the globe is
expected to propel growth at the fastest rate from 2017 to 2025
- DNA fragmentation technique for the testing of
male infertility dominated in 2016 and is estimated to generate revenue at
a rapid rate over the forecast period.
- Oxidative stress analysis is another method
gaining popularity due to accurate determination of reactive oxygen
species. The test accounted second largest share in the testing market.
- The Europe market was the largest in 2016 and
is expected to maintain its dominance during forecast period due to higher
awareness, strong diagnosis rate, and high adoption of costlier treatment.
- The industry in Asia Pacific is projected to
witness substantial growth over the next decade owing to growing
investment by several clinics and pharmaceutical companies in the region,
and increasing healthcare expenditure.
- Some key players include EMD Sereno, Inc.; Aytu
BioScience, Inc.; Bayer Healthcare; Cadila Healthcare Ltd.; Intas
Pharmaceuticals Ltd.; Halotech DNA SL; SCSA diagnostics, Inc.; and
Andrology Solutions. However, EMD Sereno, Inc. currently dominates the
male infertility market.
Browse Details of Report @ https://www.grandviewresearch.com/industry-analysis/male-infertility-market
No comments:
Post a Comment